NCT07380256 Visual Influences on Vestibular Adaptation
| NCT ID | NCT07380256 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Vestibular Hypofunction |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-02-04 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-02-04 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn whether a balance-training exercise called incremental vestibulo-ocular reflex adaptation (IVA) is safe and effective for adults with vision impairments, with or without additional vestibular (inner-ear balance) problems. The main questions it aims to answer are: * Does IVA cause only mild, temporary symptoms and no serious adverse events? * Does IVA improve eye-movement reflexes, balance, and walking, and do these improvements differ between people with vision problems alone and those with both vision and vestibular impairments? Researchers will compare adults with vision impairment only to adults who have both vision and vestibular impairments to see whether the groups respond differently to IVA. Participants will: * Complete symptom ratings before and after IVA * Undergo tests of vestibular reflexes (e.g., VOR gain) * Complete balance and walking assessments
Eligibility Criteria
Inclusion Criteria: For All Participants (All Groups) * Age 18 to 60 years * Able to provide informed consent Group-Specific Inclusion Criteria: * Group 1: Abnormal Uncorrected Static Visual Acuity (No Vestibular Hypofunction) Normal peripheral vestibular function * Group 2: Abnormal Uncorrected Static Visual Acuity + peripheral Vestibular Hypofunction * Group 3: Binocular Vision Abnormalities (No Vestibular Hypofunction) Normal peripheral vestibular function * Group 4: Binocular Vision Abnormalities + peripheral Vestibular Hypofunction Individuals who have abnormal static visual acuity, a binocular vision abnormality (ocular misalignment, convergence insufficiency), and vestibular loss will be assigned to Group 4. The following definitions will be used when determining group placement: * Abnormal Static Visual Acuity: Uncorrected visual acuity (head is still) ≥0.30 logMAR in both eyes. * Unilateral Vestibular Hypofunction: 60 ms VOR gain \<0.80 unilaterally for the lateral semicircular canal. * Bilateral Vestibular Hypofunction: 60 ms VOR gain \<0.80 bilaterally for the lateral semicircular canals. * Normal Vestibular Function: 60 ms VOR gain of 0.80 to 1.20 bilaterally for the lateral semicircular canals. * Convergence Insufficiency: ≥6 cm near point of convergence. * Ocular Misalignment: ≥4 prism diopters of manifest deviation of the eyes (tropia) on cover/uncover testing. Exclusion Criteria: * Diagnosis of fluctuating vestibular disorders (e.g., benign paroxysmal positional vertigo) * Neurologic conditions (e.g., multiple sclerosis), dementia, * Alcohol or drug abuse, * A major psychiatric disorder (e.g., schizophrenia), * Pain that limits cervical spine range of motion by \>50% or that results in an -altered gait pattern.
Contact & Investigator
Colin Grove, PT, DPT, PhD
PRINCIPAL INVESTIGATOR
Emory University
Frequently Asked Questions
Who can join the NCT07380256 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Vestibular Hypofunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07380256 currently recruiting?
Yes, NCT07380256 is actively recruiting participants. Contact the research team at colin.riess.grove@emory.edu for enrollment information.
Where is the NCT07380256 trial being conducted?
This trial is being conducted at Atlanta, United States, Atlanta, United States.
Who is sponsoring the NCT07380256 clinical trial?
NCT07380256 is sponsored by Emory University. The principal investigator is Colin Grove, PT, DPT, PhD at Emory University. The trial plans to enroll 100 participants.